Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

2018 ASCO Annual Meeting

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).

Aug

Today In Oncology

FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening

VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer

Basal Cell Carcinoma and Risk for Development of Other Cancers

Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting

;